This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Towers, G.
Right arrow Articles by Takeuchi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Towers, G.
Right arrow Articles by Takeuchi, Y.

 Previous Article  |  Next Article 

Journal of Virology, March 2002, p. 2548-2550, Vol. 76, No. 5
0022-538X/02/$04.00+0     DOI: 10.1128/jvi.76.5.2548-2550.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Abrogation of Ref1 Retrovirus Restriction in Human Cells

Greg Towers,* Mary Collins, and Yasuhiro Takeuchi

Wohl Virion Centre, Department of Immunology and Molecular Pathology, University College London, London W1T 4JF, United Kingdom

Received 26 September 2001/ Accepted 26 November 2001


arrow
ABSTRACT
 
We have previously described postentry restriction of murine leukemia virus in mammals. Here we characterize the block in human cells. Restricted infection kinetics are multiple hit at high virus dose, and restriction is abrogated by preexposure to restricted virus. We hypothesize that restricted capsid can titrate out the restriction factor.


arrow
TEXT
 
Phylogenetic studies of endogenous retroviral sequences in vertebrates have shown that, generally, retroviral sequences and host sequences have coevolved, suggesting that horizontal transfer between most vertebrates occurs only rarely. However, analysis of mammalian endogenous retrovirus sequences suggests that interspecies infection events between mammals are relatively frequent (7). Perhaps because of this a number of host mechanisms to restrict retroviral replication have been identified in mammalian cells, including the murine gene Fv1. We have recently described a block to N-tropic murine leukemia virus infection in a wide variety of mammalian species (11). We presumed that there were genes of Fv1-like function in other mammals and have called the human gene encoding this activity Ref1 (11). Southern blot data have shown that there are no sequences related to Fv1 in the human genome (1).

Abbreviations. MLV, murine leukemia virus; eGFP, enhanced green fluorescent protein; LacZ, ß-galactosidase; FACS, flow-assisted cell sorting; CA, capsid; N-eGFP and B-eGFP, N- and B-tropic eGFP pseudotypes, respectively; MDTF, Mus dunni tail fibroblast; IU, infectious unit; N-LNCX and B-LNCX, N- and B-tropic LNCX vector, respectively.

The Ref1-mediated block in human cells is during reverse transcription (11), whereas in murine cells restricted virus finishes reverse transcription (6). Otherwise, the restricted phenotypes are similar and virus particles containing mixed N- and B-tropic CA are restricted in human cells. This suggests that Ref1 is also a dominant inhibitor of restricted retrovirus infection (11). However, these data could also be explained by less-efficient interaction of N-tropic CA with cellular factors essential for MLV infection of human cells.

Retrovirus restriction in mice can be overcome when restricted cells are challenged with high virus doses (4). Furthermore, restriction can be abrogated by prior exposure of the target cells to restricted virus (2), suggesting that CA protein in restricted virions binds to and titrates out a limited pool of Fv1 protein. Here we show that Ref1 restriction can be abrogated in a similar manner, providing further evidence that Ref1 is a factor which blocks retrovirus infection of human cells.

To measure retrovirus infection we packaged retroviral vectors encoding marker genes into N- and B-tropic retroviral cores pseudotyped with the G protein from vesicular stomatitis virus as previously described (11). N-eGFP and B-eGFP had similar titers on unrestricted, Fv1-null, MDTF cells (data not shown). Serial dilutions of virus were used to infect human rhabdomyosarcoma TE671 cells. Infected cells were measured by FACS. Figure 1 shows that at low virus doses B-eGFP vector infected TE671 cells approximately 100-fold more efficiently than N-tropic virus. Infection by unrestricted B-eGFP vector on TE671 cells was linear with respect to virus dose, with a gradient of 1 except at high virus doses, at which the slope decreased. This is a typical pattern of single-hit infection, where infection events increase linearly until a significant cell population is multiply infected. In contrast, the slope of restricted N-eGFP vector infection plotted versus virus dose deviated from 1 and became steeper when more than 0.5% of the cells were infected. In the range of 1 to 30% of cells being infected, the gradient was approximately 2. This suggests two-hit infection kinetics, where exposure to an initial, restricted virion facilitates infection by a second, restricted virion. At high virus doses, the difference in infection efficiency between N- and B-tropic viruses was reduced. This behavior is similar to that noted in some studies of Fv1-restricted viruses in murine cells (3, 8, 10). However, it should be noted that other studies show single-hit curves for restricted virus on murine cells (5). The reasons for these discrepancies are not clear, but as is shown here for human cells, virus dose is important. These titration experiments were also performed on HeLa cells with similar results (data not shown).



View larger version (18K):
[in this window]
[in a new window]
  		FIG. 1. Titration curve of N- and B-tropic vectors on human cells. Human TE671 cells were infected with serial dilutions of N-eGFP ({blacksquare}) and B-eGFP ({blacktriangleup}) vectors. The percentages of cells infected were determined 48 h postinfection by FACS. Data are representative of three independent experiments.

We then examined whether preexposure of TE671 cells to N- or B-tropic virus would abrogate the restriction of N-eGFP vector. Infection by restricted N-eGFP vector was measured with or without preexposure of the target cells to N- or B-tropic pseudotypes with a lacZ gene (N-lacZ or B-lacZ vectors, respectively). Figure 2, panels i and iii, show that infection of TE671 cells with restricted N-eGFP vector was largely abrogated when cells were preexposed to N-lacZ for 6 h. There was no significant increase in the infection of unrestricted B-eGFP virus after preexposure to N-lacZ (Fig. 2, panels ii and iv), and there was no significant change in the titer of N- or B-eGFP virus after preexposure to B-lacZ (Fig. 2, panels v and vi). These data show that only preexposure to restricted N-lacZ was able to affect the titer of a second input of restricted virus. The time of preexposure to lacZ vectors was also varied in order to determine the optimal condition for abrogation of Ref1 restriction in TE671 cells. TE671 cells (105) were preexposed to N-lacZ vector for 1 to 12 h and then infected with 8,000 MDTF IU of N-eGFP vector (Fig. 3). The time course shows that the maximal abrogation was achieved with 6 h of preexposure to N-lacZ vector.



View larger version (23K):
[in this window]
[in a new window]
  		FIG. 2. Abrogation of restriction by preexposure to N-lacZ vector. Panels are side scatter versus fluorescence FACS dot plots of human TE671 cells 48 h after infection with MLV eGFP-encoding vectors. Fluorescence units are arbitrary. The gate used to determine percentages of infected cells is shown (panel i). N- and B-tropic virus titers were equalized on MDTF cells, and the N- and B-lacZ dose was 0.3 MDTF IU/TE671 cell. The N- and B-eGFP dose was ~8,000 MDTF IU. Cells were infected with N-eGFP vector (panels i, iii, and v) and B-eGFP vector (panels ii, iv, and vi). Cells in panels iii and iv were preexposed to N-lacZ vector for 6 h prior to eGFP vector infection, and panels v and vi were preexposed to B-lacZ vector for 6 h prior to eGFP vector infection. Cells were washed once in medium after exposure to lacZ vectors prior to exposure to eGFP vectors. These data are representative of three independent experiments.



View larger version (25K):
[in this window]
[in a new window]
  		FIG. 3. Time course of abrogation. TE671 cells were preexposed to abrogating N-lacZ vector (0.1 MDTF IU/TE671 cell) for periods of 1 to 12 h and then infected with a fixed titer of N-eGFP vector (~8,000 MDTF IU). Infection was measured by FACS 24 h post-N-eGFP infection. Infection of N-eGFP was maximal after 6 h of preexposure to N-lacZ. These data are representative of three independent experiments.

We then measured how much virus was required to cause abrogation using N- and-B tropic LNCX vector. N- and B-LNCX titers were equalized on MDTF cells by infection, followed by G418 selection and colony counting (data not shown). Serial dilutions of N- and B-LNCX vectors were used to preexpose TE671 cells, followed by infection with a fixed dose of N or B-eGFP vectors. Results are shown in Fig. 4, where the percentage of cells that are infected by N- or B-eGFP is plotted against the dose of abrogating LNCX vector used. As shown in Fig. 2, preexposure of cells had no significant effect on infection by unrestricted B-eGFP vector. However, the infection by restricted N-eGFP was increased by preexposure to N-LNCX in a dose-dependent manner. Preexposure to unrestricted B-tropic LNCX had no effect, even at high doses. Abrogation of N-eGFP restriction was achieved by preexposure to approximately 0.2 IU of N-LNCX per cell. We have previously shown that vector preparations typically contain around 300 physical particles per IU (9). This implies that a dose of around 60 particles/cell is enough to abrogate restriction.



View larger version (17K):
[in this window]
[in a new window]
  		FIG. 4. Titration of LNCX virus for abrogation of N-eGFP vector restriction. TE671 cells were preexposed to a serial dilution of sixfold-concentrated abrogating N- or B-LNCX virus for 6 h and then infected with a fixed titer of either N- or B-eGFP vector. Cells were analyzed for eGFP expression 48 h later. N- and B-eGFP titers were equalized on MDTF cells, and around 10,000 MDTF IU was used per point. A titer of 105 IU/ml for N-LNCX and B-LNCX was measured on MDTF cells by measurement of CFU after treatment with G418 (1 mg/ml). Data are representative of several experiments performed with LNCX and lacZ abrogating vectors.

Finally, we examined the kinetics of N-eGFP infection after preexposure to lacZ vector under conditions that resulted in maximal abrogation of restriction. Cells were preexposed to 0.3 MDTF IU of N-lacZ vector per cell for 6 h and then exposed to a serial dilution of N- or B-eGFP vectors. Figure 5 shows that after preexposure to N-lacZ vector, both N- and B-eGFP vectors showed similar linear titration curves with a gradient of 1. These results indicate that abrogation of restriction by preexposure to N-tropic virions enabled N-eGFP vector to infect cells with an efficiency and a one-hit infection curve similar to those of unrestricted B-eGFP vector.



View larger version (16K):
[in this window]
[in a new window]
  		FIG. 5. Titration curve of N-eGFP vector after abrogation of restriction. TE671 cells were infected with serial dilutions of N-eGFP ({blacklozenge}) and B-eGFP ({blacksquare}) vectors without preexposure and N-eGFP ({blacktriangleup}) and B-eGFP (•) vectors after 6 h of preexposure to an abrogating dose (0.3 MDTF IU/TE671 cell) of N-lacZ vector. Infection was measured 48 h postinfection by FACS. Data are representative of two independent experiments.

We hypothesize that the product of a human gene, Ref1, blocks N-tropic MLV infection. The Ref1 gene product is limiting and can be titrated out by excess restricted virus particles. Direct interaction between Ref1 and restricted, but not unrestricted, CAs can explain its specificity. This hypothesis is supported by the fact that the N-eGFP titration pattern after N-lacZ preexposure resembled that of unrestricted B-eGFP (Fig. 5). We suggest that humans and other nonmurine species resistant to N-tropic infection have acquired and maintained genes that are perhaps unrelated at the sequence level to Fv1 but have very similar functions. Further study of these restrictions will lead to greater understanding of how mammals have dealt with pathogenic retroviruses in the long term and how these retroviruses have shaped the human genome during evolution.


arrow
ACKNOWLEDGMENTS
 
We thank our colleagues in the Department of Immunology and Molecular Pathology at University College London for helpful discussion and J. P. Stoye of the National Institute for Medical Research for helpful discussion of unpublished data.

This work was funded by the Biotechnology and Biological Sciences Research Council, the Medical Research Council, and a research career development fellowship (number 064257) from the Wellcome Trust to G.T.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Wohl Virion Centre, Department of Immunology and Molecular Pathology, University College London, 46 Cleveland St., London W1T 4JF, United Kingdom. Phone: 44-20-7679-9569. Fax: 44-20-7679-9555. E-mail: g.towers{at}ucl.ac.uk. Back


arrow
REFERENCES
 
    1
  1. Best, S., P. Le Tissier, G. Towers, and J. P. Stoye. 1996. Positional cloning of the mouse restriction gene Fv1. Nature 382:826-829.[CrossRef][Medline]
    2. 2
  2. Boone, L. R., C. L. Innes, and C. K. Heitman. 1990. Abrogation of Fv-1 restriction by genome-deficient virions produced by a retrovirus packaging cell line. J. Virol. 64:3376-3381.[Abstract/Free Full Text]
    3. 3
  3. Decleve, A., O. Niwa, E. Gelmann, and H. S. Kaplan. 1975. Replication kinetics of N- and B-tropic murine leukemia viruses on permissive and nonpermissive cells in vitro. Virology 65:320-332.[CrossRef][Medline]
    4. 4
  4. Hartley, J. W., W. P. Rowe, and R. J. Huebner. 1970. Host-range restrictions of murine leukemia viruses in mouse embryo cell cultures. J. Virol. 5:221-225.[Abstract/Free Full Text]
    5. 5
  5. Jolicoeur, P., and D. Baltimore. 1975. Effect of the Fv-1 locus on the titration of murine leukemia viruses. J. Virol. 16:1593-1598.[Abstract/Free Full Text]
    6. 6
  6. Jolicoeur, P., and E. Rassart. 1980. Effect of Fv-1 gene product on synthesis of linear and supercoiled viral DNA in cells infected with murine leukemia virus. J. Virol. 33:183-195.[Abstract/Free Full Text]
    7. 7
  7. Martin, J., E. Herniou, J. Cook, R. W. O'Neill, and M. Tristem. 1999. Interclass transmission and phyletic host tracking in murine leukemia virus-related retroviruses. J. Virol. 73:2442-2449.[Abstract/Free Full Text]
    8. 8
  8. Pincus, T., W. P. Rowe, and F. Lilly. 1971. A major genetic locus affecting resistance to infection with murine leukemia viruses. II. Apparent identity to a major locus described for resistance to friend murine leukemia virus. J. Exp. Med. 133:1234-1241.[Abstract]
    9. 9
  9. Pizzato, M., S. A. Marlow, E. D. Blair, and Y. Takeuchi. 1999. Initial binding of murine leukemia virus particles to cells does not require specific Env-receptor interaction. J. Virol. 73:8599-8611.[Abstract/Free Full Text]
    10. 10
  10. Tennant, R. W., J. A. Otten, A. Brown, W. K. Yang, and S. J. Kennel. 1979. Characterization of Fv-1 host range strains of murine retroviruses by titration and p30 protein characteristics. Virology 99:349-357.[CrossRef][Medline]
    11. 11
  11. Towers, G., M. Bock, S. Martin, Y. Takeuchi, J. P. Stoye, and O. Danos. 2000. A conserved mechanism of retrovirus restriction in mammals. Proc. Natl. Acad. Sci. USA 97:12295-12299.[Abstract/Free Full Text]

Journal of Virology, March 2002, p. 2548-2550, Vol. 76, No. 5
0022-538X/02/$04.00+0     DOI: 10.1128/jvi.76.5.2548-2550.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Sebastian, S., Grutter, C., de Castillia, C. S., Pertel, T., Olivari, S., Grutter, M. G., Luban, J. (2009). An Invariant Surface Patch on the TRIM5{alpha} PRYSPRY Domain Is Required for Retroviral Restriction but Dispensable for Capsid Binding. J. Virol. 83: 3365-3373 [Abstract] [Full Text]  
  • Luban, J. (2007). Cyclophilin A, TRIM5, and Resistance to Human Immunodeficiency Virus Type 1 Infection. J. Virol. 81: 1054-1061 [Full Text]  
  • Ohkura, S., Yap, M. W., Sheldon, T., Stoye, J. P. (2006). All Three Variable Regions of the TRIM5{alpha} B30.2 Domain Can Contribute to the Specificity of Retrovirus Restriction.. J. Virol. 80: 8554-8565 [Abstract] [Full Text]  
  • Ylinen, L. M. J., Keckesova, Z., Webb, B. L. J., Gifford, R. J. M., Smith, T. P. L., Towers, G. J. (2006). Isolation of an Active Lv1 Gene from Cattle Indicates that Tripartite Motif Protein-Mediated Innate Immunity to Retroviral Infection Is Widespread among Mammals.. J. Virol. 80: 7332-7338 [Abstract] [Full Text]  
  • Wu, X., Anderson, J. L., Campbell, E. M., Joseph, A. M., Hope, T. J. (2006). Proteasome inhibitors uncouple rhesus TRIM5{alpha} restriction of HIV-1 reverse transcription and infection. Proc. Natl. Acad. Sci. USA 103: 7465-7470 [Abstract] [Full Text]  
  • Si, Z., Vandegraaff, N., O'hUigin, C., Song, B., Yuan, W., Xu, C., Perron, M., Li, X., Marasco, W. A., Engelman, A., Dean, M., Sodroski, J. (2006). Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts retroviral infection. Proc. Natl. Acad. Sci. USA 103: 7454-7459 [Abstract] [Full Text]  
  • Sokolskaja, E., Berthoux, L., Luban, J. (2006). Cyclophilin A and TRIM5{alpha} Independently Regulate Human Immunodeficiency Virus Type 1 Infectivity in Human Cells. J. Virol. 80: 2855-2862 [Abstract] [Full Text]  
  • Passerini, L. D., Keckesova, Z., Towers, G. J. (2006). Retroviral Restriction Factors Fv1 and TRIM5{alpha} Act Independently and Can Compete for Incoming Virus before Reverse Transcription. J. Virol. 80: 2100-2105 [Abstract] [Full Text]  
  • Saenz, D. T., Teo, W., Olsen, J. C., Poeschla, E. M. (2005). Restriction of Feline Immunodeficiency Virus by Ref1, Lv1, and Primate TRIM5{alpha} Proteins. J. Virol. 79: 15175-15188 [Abstract] [Full Text]  
  • Ylinen, L. M. J., Keckesova, Z., Wilson, S. J., Ranasinghe, S., Towers, G. J. (2005). Differential Restriction of Human Immunodeficiency Virus Type 2 and Simian Immunodeficiency Virus SIVmac by TRIM5{alpha} Alleles. J. Virol. 79: 11580-11587 [Abstract] [Full Text]  
  • Dodding, M. P., Bock, M., Yap, M. W., Stoye, J. P. (2005). Capsid Processing Requirements for Abrogation of Fv1 and Ref1 Restriction. J. Virol. 79: 10571-10577 [Abstract] [Full Text]  
  • Lesner, A., Li, Y., Nitkiewicz, J., Li, G., Kartvelishvili, A., Kartvelishvili, M., Simm, M. (2005). A Soluble Factor Secreted by an HIV-1-Resistant Cell Line Blocks Transcription through Inactivating the DNA-Binding Capacity of the NF-{kappa}B p65/p50 Dimer. J. Immunol. 175: 2548-2554 [Abstract] [Full Text]  
  • Marchant, D., Neil, S. J. D., Aubin, K., Schmitz, C., McKnight, A. (2005). An Envelope-Determined, pH-Independent Endocytic Route of Viral Entry Determines the Susceptibility of Human Immunodeficiency Virus Type 1 (HIV-1) and HIV-2 to Lv2 Restriction. J. Virol. 79: 9410-9418 [Abstract] [Full Text]  
  • Javanbakht, H., Diaz-Griffero, F., Stremlau, M., Si, Z., Sodroski, J. (2005). The Contribution of RING and B-box 2 Domains to Retroviral Restriction Mediated by Monkey TRIM5{alpha}. J. Biol. Chem. 280: 26933-26940 [Abstract] [Full Text]  
  • Song, B., Gold, B., O'hUigin, C., Javanbakht, H., Li, X., Stremlau, M., Winkler, C., Dean, M., Sodroski, J. (2005). The B30.2(SPRY) Domain of the Retroviral Restriction Factor TRIM5{alpha} Exhibits Lineage-Specific Length and Sequence Variation in Primates. J. Virol. 79: 6111-6121 [Abstract] [Full Text]  
  • Song, B., Javanbakht, H., Perron, M., Park, D. H., Stremlau, M., Sodroski, J. (2005). Retrovirus Restriction by TRIM5{alpha} Variants from Old World and New World Primates. J. Virol. 79: 3930-3937 [Abstract] [Full Text]  
  • Stremlau, M., Perron, M., Welikala, S., Sodroski, J. (2005). Species-Specific Variation in the B30.2(SPRY) Domain of TRIM5{alpha} Determines the Potency of Human Immunodeficiency Virus Restriction. J. Virol. 79: 3139-3145 [Abstract] [Full Text]  
  • Forshey, B. M., Shi, J., Aiken, C. (2005). Structural Requirements for Recognition of the Human Immunodeficiency Virus Type 1 Core during Host Restriction in Owl Monkey Cells. J. Virol. 79: 869-875 [Abstract] [Full Text]  
  • Sayah, D. M., Luban, J. (2004). Selection for Loss of Ref1 Activity in Human Cells Releases Human Immunodeficiency Virus Type 1 from Cyclophilin A Dependence during Infection. J. Virol. 78: 12066-12070 [Abstract] [Full Text]  
  • Keckesova, Z., Ylinen, L. M. J., Towers, G. J. (2004). The human and African green monkey TRIM5{alpha} genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. USA 101: 10780-10785 [Abstract] [Full Text]  
  • Hatziioannou, T., Cowan, S., von Schwedler, U. K., Sundquist, W. I., Bieniasz, P. D. (2004). Species-Specific Tropism Determinants in the Human Immunodeficiency Virus Type 1 Capsid. J. Virol. 78: 6005-6012 [Abstract] [Full Text]  
  • Owens, C. M., Song, B., Perron, M. J., Yang, P. C., Stremlau, M., Sodroski, J. (2004). Binding and Susceptibility to Postentry Restriction Factors in Monkey Cells Are Specified by Distinct Regions of the Human Immunodeficiency Virus Type 1 Capsid. J. Virol. 78: 5423-5437 [Abstract] [Full Text]  
  • Schmitz, C., Marchant, D., Neil, S. J. D., Aubin, K., Reuter, S., Dittmar, M. T., McKnight, A. (2004). Lv2, a Novel Postentry Restriction, Is Mediated by both Capsid and Envelope. J. Virol. 78: 2006-2016 [Abstract] [Full Text]  
  • Hatziioannou, T., Cowan, S., Bieniasz, P. D. (2004). Capsid-Dependent and -Independent Postentry Restriction of Primate Lentivirus Tropism in Rodent Cells. J. Virol. 78: 1006-1011 [Abstract] [Full Text]  
  • Besnier, C., Ylinen, L., Strange, B., Lister, A., Takeuchi, Y., Goff, S. P., Towers, G. J. (2003). Characterization of Murine Leukemia Virus Restriction in Mammals. J. Virol. 77: 13403-13406 [Abstract] [Full Text]  
  • Berthoux, L., Towers, G. J., Gurer, C., Salomoni, P., Pandolfi, P. P., Luban, J. (2003). As2O3 Enhances Retroviral Reverse Transcription and Counteracts Ref1 Antiviral Activity. J. Virol. 77: 3167-3180 [Abstract] [Full Text]  
  • Kootstra, N. A., Munk, C., Tonnu, N., Landau, N. R., Verma, I. M. (2003). Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc. Natl. Acad. Sci. USA 100: 1298-1303 [Abstract] [Full Text]  
  • Munk, C., Brandt, S. M., Lucero, G., Landau, N. R. (2002). A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc. Natl. Acad. Sci. USA 99: 13843-13848 [Abstract] [Full Text]  
  • Cowan, S., Hatziioannou, T., Cunningham, T., Muesing, M. A., Gottlinger, H. G., Bieniasz, P. D. (2002). From the Cover: Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. USA 99: 11914-11919 [Abstract] [Full Text]  
  • Besnier, C., Takeuchi, Y., Towers, G. (2002). Restriction of lentivirus in monkeys. Proc. Natl. Acad. Sci. USA 99: 11920-11925 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Towers, G.
Right arrow Articles by Takeuchi, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Towers, G.
Right arrow Articles by Takeuchi, Y.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»